Home Tags Gilead Sciences
Tag: Gilead Sciences
The treatment made by Gilead combines three drugs into one daily pill: bictegravir, emtricitabine and tenofovir alafenamide.
The treatment, called Yescarta, treats a type of blood cancer called aggressive B-cell non-Hodgkin lymphoma.
One of the most anticipated biotech deals of the year slotted into place after a fateful July meeting that didn't directly have to do with either company.
A medical breakthrough that hacks genes to fight cancer just got approved, and it’s the beginning of ‘a big new field of medicine’
On Wednesday, the FDA approved Kymriah, the first gene therapy in the US. Known as CAR T-cell therapy, it harnesses the body's immune system to fight cancer.
After several quiet years, Gilead made a splashy return to M&A Monday, buying cancer-immunotherapy firm Kite Pharma for $11.9 billion in cash, a 29% premium.
Why Gilead bought Kite Pharma for $12 billion
Gilead is paying $11.9 billion for Kite Pharma, a company that makes cell therapies that target the body's immune system to fight cancer.
Shares of biotech company Gilead were down as much as 4% after-hours Tuesday after revealing a disappointing guidance for 2017.
Close to 8,500 people have been treated for hepatitis C in Georgia using new medications that cure patients of the disease.
Epclusa is able to treat any kind of hepatitis C genotype with in one pill that's taken once a day for 12 weeks, according to the FDA.